611 results on '"Rizos, Helen"'
Search Results
2. Circulating tumour DNA dynamics predict recurrence in stage III melanoma patients receiving neoadjuvant immunotherapy
3. PKC-independent PI3K signalling diminishes PKC inhibitor sensitivity in uveal melanoma
4. Single-cell RNA sequencing reveals melanoma cell state-dependent heterogeneity of response to MAPK inhibitors
5. The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma
6. Single-cell RNA sequencing in melanoma: what have we learned so far?
7. IFN-γ Signaling Sensitizes Melanoma Cells to BH3 Mimetics
8. Protein kinase inhibitor responses in uveal melanoma reflects a diminished dependency on PKC-MAPK signaling
9. Five-year analysis of neoadjuvant dabrafenib and trametinib for stage III melanoma
10. Repurposing Melanoma Chemotherapy to Activate Inflammasomes in the Treatment of BRAF/MAPK Inhibitor Resistant Melanoma
11. Biology of Melanocytes and Primary Melanoma
12. Emerging Novel Therapies in Overcoming Resistance to Targeted Therapy
13. Ex vivo tissue modelling informs drug selection for rare cancers
14. Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms
15. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium
16. Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial
17. Evaluation of commercial kits for purification of circulating free DNA
18. Response of BRAF-Mutant Melanoma to BRAF Inhibition Is Mediated by a Network of Transcriptional Regulators of Glycolysis
19. Ex vivo tissue modelling informs drug selection for rare cancers.
20. Single cell profiling of tumour biopsies and heterogeneity in response of dedifferentiated melanoma.
21. The Role of Sumoylation in Senescence
22. Senescence
23. Pharmacokinetic and cytokine profiles of melanoma patients with dabrafenib and trametinib-induced pyrexia
24. Monitoring Melanoma Using Circulating Free DNA
25. Immune cell profiling in the age of immune checkpoint inhibitors: implications for biomarker discovery and understanding of resistance mechanisms
26. Supplementary Figure S1 from Intratumoral CD16+ Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
27. Supplementary Table S1 from Intratumoral CD16+ Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
28. Whole genome landscapes of uveal melanoma show an ultraviolet radiation signature in iris tumours
29. Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition
30. Checkpoint kinase 1 inhibitor + low‐dose hydroxyurea efficiently kills BRAF inhibitor‐ and immune checkpoint inhibitor‐resistant melanomas.
31. Biology of Melanocytes and Primary Melanoma
32. Data from Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma
33. Figure S2 from Somatic Hypermutation of the YAP Oncogene in a Human Cutaneous Melanoma
34. Supplementary Data 2 from Response of BRAF-Mutant Melanoma to BRAF Inhibition Is Mediated by a Network of Transcriptional Regulators of Glycolysis
35. Supplementary Tables S1-S15 from Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma
36. Supplementary Figure 3 from Antiproliferative Effects of Continued Mitogen-Activated Protein Kinase Pathway Inhibition following Acquired Resistance to BRAF and/or MEK Inhibition in Melanoma
37. Supplementary Figure 1 from Antiproliferative Effects of Continued Mitogen-Activated Protein Kinase Pathway Inhibition following Acquired Resistance to BRAF and/or MEK Inhibition in Melanoma
38. Supplementary Text, Figure Legends, Figures S1-S12 from Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma
39. Supplementary Methods from Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma
40. Data from Response of BRAF-Mutant Melanoma to BRAF Inhibition Is Mediated by a Network of Transcriptional Regulators of Glycolysis
41. Data from Antiproliferative Effects of Continued Mitogen-Activated Protein Kinase Pathway Inhibition following Acquired Resistance to BRAF and/or MEK Inhibition in Melanoma
42. Supplementary Data 1 from Response of BRAF-Mutant Melanoma to BRAF Inhibition Is Mediated by a Network of Transcriptional Regulators of Glycolysis
43. Supplementary Methods from Response of BRAF-Mutant Melanoma to BRAF Inhibition Is Mediated by a Network of Transcriptional Regulators of Glycolysis
44. Supplementary Figure 2 from Antiproliferative Effects of Continued Mitogen-Activated Protein Kinase Pathway Inhibition following Acquired Resistance to BRAF and/or MEK Inhibition in Melanoma
45. Supplemental Legends from Somatic Hypermutation of the YAP Oncogene in a Human Cutaneous Melanoma
46. Supplementary Figures and Tables from Response of BRAF-Mutant Melanoma to BRAF Inhibition Is Mediated by a Network of Transcriptional Regulators of Glycolysis
47. Supplementary Figure 6 from Antiproliferative Effects of Continued Mitogen-Activated Protein Kinase Pathway Inhibition following Acquired Resistance to BRAF and/or MEK Inhibition in Melanoma
48. Supplementary Figure Legend from Antiproliferative Effects of Continued Mitogen-Activated Protein Kinase Pathway Inhibition following Acquired Resistance to BRAF and/or MEK Inhibition in Melanoma
49. Supplementary Figure 5 from Antiproliferative Effects of Continued Mitogen-Activated Protein Kinase Pathway Inhibition following Acquired Resistance to BRAF and/or MEK Inhibition in Melanoma
50. Supplementary Figure 4 from Antiproliferative Effects of Continued Mitogen-Activated Protein Kinase Pathway Inhibition following Acquired Resistance to BRAF and/or MEK Inhibition in Melanoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.